Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Eos Energy Enterprises Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.65 (market cap $4.49B), while Eos Energy Enterprises Inc trades at $4.49 (market cap $1.68B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.7× Eos Energy Enterprises Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | EOSE | |
|---|---|---|
Market Cap | $4.49B | $1.68B |
Sector | Health | Energy |
52-Week High | $28.06 | $19.19 |
52-Week Low | $20.06 | $4.40 |
Enterprise Value | $3.69B | $1.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EOSE trades at $5.06, down 3.25% today, amid a bearish technical signal despite a recent Q1 2026 earnings beat. The company shows rapid revenue growth but deep losses, with a net income margin of -296.13% in 2026. Recent news highlights progress in its Frontier Power USA venture and new supply agreements, yet cash flow remains negative from operations, relying on financing.
The outlook is mixed: analyst consensus is a Buy with a $8.33 price target, signaling potential upside, but high execution risk persists given substantial losses and a debt-to-asset ratio of 91.87%. Investors face volatility from operational cash burn against growth initiatives in the competitive energy storage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
